Long-term efficacy and safety of topical PRK 124 (0.125%) lotion (Pyratine-XR) in the treatment of mild-to-moderate rosacea.
Journal of Drugs in Dermatology › Vol. 9 Nbr. 6, June 2010
Linked as:
Summary
ORIGINAL ARTICLES - Report
See the full content of this document
Extract
Long-term efficacy and safety of topical PRK 124 (0.125%) lotion (Pyratine-XR) in the treatment of mild-to-moderate rosacea.
ABSTRACT
Background: Many patients with rosacea cannot tolerate extended treatment periods with topical agents because their skin sensitivity is often increased. Objective: To determine the long-term efficacy and tolerability of a new moisturizing lotion for improving the signs and symptoms of mild-to-moderate rosacea. Methods: In a 48-week, open-label study, a moisturizing lotion containing furfuryl tetrahydropyranyladenine as PRK-124 (0.125%, Pyratine-XR[TM], Senetek PLC, Napa, CA) was applied twice daily by 18 subjects with mild-to-moderate rosacea. Clinical improvements were assessed by the treating physi...See the full content of this document
Sponsored links
